Florence Portet

Summary

Publications

  1. ncbi [Parkinson's disease dementia and Lewy body dementia]
    Florence Portet
    centre mémoire de ressource et de recherche, Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier
    Psychol Neuropsychiatr Vieil 4:S35-50. 2006
  2. ncbi Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study
    Florence Portet
    Memory Research Resource Center for Alzheimer s Disease, Neurology Department, U 888 Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Montpellier, France
    Arch Neurol 66:1120-6. 2009
  3. ncbi Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease
    F Portet
    Memory Research Resource Center for Alzheimer s Disease, Neurology B Department, Institut National de la Sante et de la Recherche Medicale, Montpellier Hospital, Montpellier, France
    J Neurol Neurosurg Psychiatry 77:714-8. 2006
  4. ncbi [What is a mild cognitive impairment?]
    Florence Portet
    Centre mémoire ressources et recherche CM2R du Languedoc Roussillon, Neurologie B, Inserm E 361, CHU de Montpellier, 34295 Montpellier
    Rev Prat 55:1891-4. 2005
  5. ncbi Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu)
    F Portet
    UNCD, Gui de Chauliac Hospital, Montpellier, France
    Neurology 61:1136-7. 2003
  6. ncbi Cognitive impairment in motor neuron disease with bulbar onset
    F Portet
    Unité de Neurologie Comportementale et dégénérativel, Hĵpital Gui de Chauliac, Montpellier, France
    Amyotroph Lateral Scler Other Motor Neuron Disord 2:23-9. 2001
  7. ncbi Metabolic syndrome and localization of white matter hyperintensities in the elderly population
    Florence Portet
    INSERM, Unit 1061, Neuropsychiatry, Epidemiological and Clinical Research, Montpellier, France
    Alzheimers Dement 8:S88-95.e1. 2012
  8. ncbi [Mild cognitive impairment]
    Jacques Touchon
    Service de Neurologie, CM2R du Languedoc Roussillon, Inserm E 361, CHU, Montpellier Cedex 05
    Presse Med 36:1464-8. 2007
  9. ncbi Spatial distribution of cerebral white matter lesions predicts progression to mild cognitive impairment and dementia
    Marion Mortamais
    INSERM, U1061, La Colombière Hospital, Montpellier, France
    PLoS ONE 8:e56972. 2013
  10. ncbi Caffeine, cognitive functioning, and white matter lesions in the elderly: establishing causality from epidemiological evidence
    Karen Ritchie
    INSERM, U888, Montpellier, France and University of Montpellier 1, Montpellier, France
    J Alzheimers Dis 20:S161-6. 2010

Detail Information

Publications26

  1. ncbi [Parkinson's disease dementia and Lewy body dementia]
    Florence Portet
    centre mémoire de ressource et de recherche, Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier
    Psychol Neuropsychiatr Vieil 4:S35-50. 2006
    ..It becomes essential to better define the boundaries of these cerebral neurodegenerative diseases. The perspective of common physiopathological mechanisms and certain vulnerability profiles could lead to new therapeutic pathways...
  2. ncbi Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study
    Florence Portet
    Memory Research Resource Center for Alzheimer s Disease, Neurology Department, U 888 Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Montpellier, France
    Arch Neurol 66:1120-6. 2009
    ..Extrapyramidal signs (EPSs) are commonly accepted as a feature of Alzheimer disease (AD) and may influence both the profile of impairment and prognosis...
  3. ncbi Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease
    F Portet
    Memory Research Resource Center for Alzheimer s Disease, Neurology B Department, Institut National de la Sante et de la Recherche Medicale, Montpellier Hospital, Montpellier, France
    J Neurol Neurosurg Psychiatry 77:714-8. 2006
    ....
  4. ncbi [What is a mild cognitive impairment?]
    Florence Portet
    Centre mémoire ressources et recherche CM2R du Languedoc Roussillon, Neurologie B, Inserm E 361, CHU de Montpellier, 34295 Montpellier
    Rev Prat 55:1891-4. 2005
    ..cognitive impairment does not have any repercussions on daily life, the subject may report difficulties concerning complex day-to-day activities; (5.) no dementia...
  5. ncbi Very early onset AD with a de novo mutation in the presenilin 1 gene (Met 233 Leu)
    F Portet
    UNCD, Gui de Chauliac Hospital, Montpellier, France
    Neurology 61:1136-7. 2003
    ..The authors describe a 28-year-old woman with histopathologically confirmed early onset Alzheimer disease characterized by severe frontal lobe involvement associated with a de novo mutation in the presenilin 1 gene (PSEN1)...
  6. ncbi Cognitive impairment in motor neuron disease with bulbar onset
    F Portet
    Unité de Neurologie Comportementale et dégénérativel, Hĵpital Gui de Chauliac, Montpellier, France
    Amyotroph Lateral Scler Other Motor Neuron Disord 2:23-9. 2001
    ..Cognitive impairment was defined by clinical evidence of dementia (DSM-IV and frontal evaluation) or by significant alteration indicated by neuropsychological testing (excluding patients with depression and major anxiety), or both...
  7. ncbi Metabolic syndrome and localization of white matter hyperintensities in the elderly population
    Florence Portet
    INSERM, Unit 1061, Neuropsychiatry, Epidemiological and Clinical Research, Montpellier, France
    Alzheimers Dement 8:S88-95.e1. 2012
    ....
  8. ncbi [Mild cognitive impairment]
    Jacques Touchon
    Service de Neurologie, CM2R du Languedoc Roussillon, Inserm E 361, CHU, Montpellier Cedex 05
    Presse Med 36:1464-8. 2007
    ..Biological and radiological markers will provide greater and more systematic support for diagnosis in the near future, particularly for early detection of Alzheimer's disease...
  9. ncbi Spatial distribution of cerebral white matter lesions predicts progression to mild cognitive impairment and dementia
    Marion Mortamais
    INSERM, U1061, La Colombière Hospital, Montpellier, France
    PLoS ONE 8:e56972. 2013
    ..We sought to determine whether a particular WML profile, based on the density and location of lesions, could be associated with an increased risk of mild cognitive impairment (MCI) or dementia over the following 7 years...
  10. ncbi Caffeine, cognitive functioning, and white matter lesions in the elderly: establishing causality from epidemiological evidence
    Karen Ritchie
    INSERM, U888, Montpellier, France and University of Montpellier 1, Montpellier, France
    J Alzheimers Dis 20:S161-6. 2010
    ..The significant relationship observed between caffeine intake in women and lower cognitive decline is highly likely to be a true causal relationship and not a spurious association...
  11. ncbi Olive oil and cognition: results from the three-city study
    Claudine Berr
    INSERM U888 Pathologies du Systeme Nerveux Recherche Epidemiologique et Clinique, Universite Montpellier 1, Montpellier, France
    Dement Geriatr Cogn Disord 28:357-64. 2009
    ..Aim of the Study: Our objective was to examine the association between olive oil use, cognitive deficit and cognitive decline in a large elderly population...
  12. ncbi 'I think therefore I am': improving cognition
    Karen Ritchie
    French National Institute of Health and Medical Research INSERM, Unit E361 Pathologies of the Nervous System, La Colombière Hospital, Montpellier, France
    Curr Opin Psychiatry 19:570-4. 2006
    ..In the absence of a specific treatment for dementia, the effective management of cognitive symptoms is a clinical priority...
  13. ncbi Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's disease
    Emilie Mas
    Department of Biochemistry, Lapeyronie Hospital, Montpellier, France
    Dement Geriatr Cogn Disord 21:198-204. 2006
    ..Our study strongly supports the hypothesis of an impairment of lipophilic antioxidant delivery to neuronal cells in AD leading to a tissular antioxidant deficiency which could facilitate oxidative stress...
  14. ncbi Depression in elderly persons subject to childhood maltreatment is not modulated by corpus callosum and hippocampal loss
    Karen Ritchie
    INSERM, U1061, Montpellier, F 34093, France University of Montpellier 1, Montpellier, F 34000, France Faculty of Medicine, Imperial College, London, United Kingdom Electronic address
    J Affect Disord 141:294-9. 2012
    ..No association was found with childhood sexual and physical abuse...
  15. ncbi GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data
    Sandrine Andrieu
    INSERM, U558, F 31073, Toulouse, France
    Curr Alzheimer Res 5:406-15. 2008
    ..5% presented a CDR score of 0.5. This study will enable us to evaluate the efficacy of EGb761 in the prevention of AD, and to assess the usefulness of various baseline characteristics as predictors of conversion to AD in this population...
  16. ncbi Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study
    Frederic Cortes
    Department of Internal Medicine and Clinical Gerontology, Centre Hospitalier Universitaire Purpan Casselardit, Toulouse, France
    Alzheimers Dement 4:22-9. 2008
    ..The aim of the present study was to describe the long-term evolution of Alzheimer's disease (AD) in a prospective cohort of patients under treatment with a close follow-up...
  17. ncbi Risk profiles for mild cognitive impairment and progression to dementia are gender specific
    S Artero
    INSERM U888, Nervous System Pathologies Epidemiological and Clinical Research, La Colombière Hospital, 34093 Montpellier Cedex 5, France
    J Neurol Neurosurg Psychiatry 79:979-84. 2008
    ..To examine risk factors for mild cognitive impairment (MCI) and progression to dementia in a prospective community-based study of subjects aged 65 years and over...
  18. ncbi The neuroprotective effects of caffeine: a prospective population study (the Three City Study)
    K Ritchie
    INSERM U888 Nervous System Pathologies, Epidemiological and Clinical Research, La Colombière Hospital, Montpellier, France
    Neurology 69:536-45. 2007
    ..To examine the association between caffeine intake, cognitive decline, and incident dementia in a community-based sample of subjects aged 65 years and over...
  19. ncbi Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    F Cortes
    F Cortes, Alzheimer s Disease Research Centre, U 558, Toulouse, France
    J Nutr Health Aging 11:330-7. 2007
    ..Clinical trials in Alzheimer's disease (AD) include patients benefiting from recent improvements in AD management...
  20. ncbi IANA task force on nutrition and cognitive decline with aging
    S Gillette Guyonnet
    Service de Medecine Interne et de Gerontologie Clinique, Pavillon J P Junod, Centre Hospitalier Universitaire La Grave Casselardit, Toulouse Cedex 9, France
    J Nutr Health Aging 11:132-52. 2007
    ..These studies must control for the greatest number of known confounding factors and take into account the impact of the standard social determinants of food habits, such as the regional cultures, social status, and educational level...
  21. ncbi [Mild cognitive impairment: imaging data]
    J Touchon
    , Neurologie B, CHU Gui-de-Chauliac, 34295 Montpellier Cedex 05 INSERM E 99-30, CHU de Montpellier
    Rev Neurol (Paris) 158:S21-9. 2002
    ..This latter technique, leading to the development of cognitive activation paradigms, is particularly promising...
  22. ncbi ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]
    B Dubois
    , , Paris
    Presse Med 31:1696-9. 2002
    ..CONCLUSION: This is a rapid (2 minutes) and simple test that is easy to use in medical practice for the screening of AD...
  23. ncbi Endpoints for trials in Alzheimer's disease: a European task force consensus
    Bruno Vellas
    INSERM U558, Toulouse, France
    Lancet Neurol 7:436-50. 2008
    ..A clear and consensual definition of endpoints is crucial for the success of further clinical trials in the field and will allow comparison of data across studies...
  24. ncbi Prevention trials in Alzheimer disease: one step forward?
    J Touchon
    Neurology Service, Guy de Chauliac Hospital, Montpellier, France
    Neurology 67:S21-2. 2006
    ..A critical concern is the benefit and relative risk of giving a treatment to non-demented patients or to asymptomatic subjects. Some trials are under way and will perhaps move the field of prevention of dementia one big step forward...
  25. ncbi [Behavioral and psychological symptoms in dementia: description and management]
    M Benoit
    , , 30, avenue de la Voie Romaine, BP 69, 06002 CHU de Nice Cedex 1, France
    Rev Neurol (Paris) 161:357-66. 2005
    ..This report was updated with the most recent literature reports, and was adapted to the French environment. This paper is a synthesis of this meeting, validated and corrected by the entire Thema 2 group...
  26. ncbi [Amyotrophic lateral sclerosis and cognitive disorders: review and analysis of the literature]
    F Portet
    , Neurologie B, CHU Montpelier
    Rev Neurol (Paris) 157:139-50. 2001
    ..Together with upper and lower motor neuron signs, sensory or cognitive impairment are not uncommon. The frequency of a multidegenerative profile in ALS with SOD1 mutations is also an argument for this. We reviewed the literature about:..